Search Within

Amin Taher Yaqubie

Formats
  1. Journal Article (13)
  2. Meeting Abstract (13)
Groups
  1. Department of Medicine (26)
  2. Solid Tumor Oncology Division (26)
  3. Gastrointestinal Oncology Service (25)
  4. Center for Pancreatic Cancer Research (15)
  5. Epidemiology and Biostatistics (14)
  6. GSK Faculty (12)

More Groups

People
  1. Ghassan Abou-Alfa (22)
  2. James Harding (15)
  3. Eileen O'Reilly (12)
  4. Imane El Dika (12)
  5. Danny Khalil (8)
  6. David Solit (8)

More People

Years
  1. 2025 (4)
  2. 2024 (5)
  3. 2023 (5)
  4. 2022 (4)
  5. 2021 (5)
  6. 2015 (1)

More Years

Publications
  1. Journal of Clinical Oncology (10)
  2. Annals of Oncology (3)
  3. Cancer Medicine (2)
  4. JCO Global Oncology (2)
  5. JCO Precision Oncology (2)
  6. The Oncologist (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (14)
  2. Oxford University Press (5)
  3. Wiley Blackwell (2)
  4. American Association for Cancer Research (1)
  5. Karger (1)
  6. Springer (1)

More Publishers

Results (26)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    El Dika, I. H.; Geyer, S. M.; Nixon, A. B.; Innocenti, F.; Shi, Q.; Jacobson, S. B.; Yaqubie, A.; Lopez, J. C.; Huang, B. H.; Tang, Y. W.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma
    Meeting Abstract

    Abou-Alfa, G. K.; Bibeau, K.; Schultz, N.; Yaqubie, A.; Millang, B. M.; Ren, H.; Feliz, L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC)
    Meeting Abstract

    Abou-Alfa, G. K.; Meyer, T.; Zhang, J.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Xu, F.; Eli, L. D.; Harding, J. J.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases
    Journal Article

    Harding, J. J.; Catalanotti, F.; Munhoz, R. R.; Cheng, D. T.; Yaqubie, A.; Kelly, N.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Lacouture, M. E.; more...
    The Oncologist (2015)

    Fulltext@MSK | Save
  • Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets)
    Meeting Abstract

    Harding, J. J.; Catalanotti, F.; Yaqubie, A.; McDermott, G. C.; Kersellius, R.; Merghoub, T.; Carvajal, R. D.; D'Angelo, S. P.; Dickson, M. A.; Schwartz, G. K.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Evolutionary dynamics of cancer in response to targeted combination therapy
    Journal Article

    Bozic, I.; Reiter, J. G.; Allen, B.; Antal, T.; Chatterjee, K.; Shah, P.; Moon, Y. S.; Yaqubie, A.; Kelly, N.; Le, D. T.; more...
    eLife (2013)

    Fulltext@MSK | Save